Ryazan Regional Clinical Hospital | Acute Cardiac Care Department

Research site

(Unclaimed)

Location

Ryazan, Street International, 3-a, Ryazan, Ryazan, Russian Federation

Site insights

Top conditions

Top treatments

Daratumumab

Bendamustine

Idelalisib

Ibrutinib

Cusatuzumab

GS-1101

Azacitidine

Obinutuzumab

Guselkumab

Zanubrutinib

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

8 of 20 total trials

A Long-term Extension Study of PCI-32765 (Ibrutinib) (CAN3001)

The purpose of this study is to collect long-term safety and efficacy data for participants treated with ibrutinib and to provide ongoing access to i...

Invitation-only

Waldenstrom Macroglobulinemia

Follicular Lymphoma

Drug: Ibrutinib

A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL (SEQUOIA)

To compare efficacy between zanubrutinib versus bendamustine and rituximab in patients with previously untreated CLL/SLL, as measured by progression...

Active, not recruiting

Small Lymphocytic Lymphoma

Chronic Lymphocytic Leukemia

Drug: Rituximab

Drug: Venetoclax

A Study of Cusatuzumab Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia Who Are Not Candidates for Intensive Chemotherapy (CULMINATE)

The purpose of this study is to determine the efficacy of cusatuzumab in combination with azacitidine in participants with previously untreated acute...

Active, not recruiting

Leukemia, Myeloid, Acute

Drug: Cusatuzumab

Drug: Azacitidine

A Study of Daratumumab

The purpose of this study is to provide ongoing access to study treatments for participants with multiple myeloma or smoldering multiple myeloma bene...

Enrolling

Multiple Myeloma

Drug: Carfilzomib

Drug: Daratumumab

A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX)

The purpose of this study is to evaluate the efficacy of guselkumab treatment in participants with active psoriatic arthritis (PsA) by assessing the...

Enrolling

Arthritis, Psoriatic

Drug: Placebo

Drug: Guselkumab

A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma

The primary objective of this study is to determine whether treatment with daratumumab administered subcutaneously (SC) prolongs progression-free sur...

Active, not recruiting

Smoldering Multiple Myeloma

Drug: Daratumumab SC: daratumumab + rHuPH20

A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (GLOW)

The purpose of this study is to assess progression-free survival (PFS) from treatment with ibrutinib plus venetoclax (I+VEN) compared with obinutuzum...

Active, not recruiting

Leukemia, Lymphocytic, Chronic, B-Cell

Drug: Obinutuzumab

Drug: Venetoclax

Study to Evaluate Imetelstat (GRN163L) in Subjects With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

The purpose of this study is to evaluate the efficacy and safety of imetelstat in transfusion-dependent participants with low or intermediate-1 risk...

Active, not recruiting

Myelodysplastic Syndromes

Drug: Placebo

Drug: Imetelstat